Description: Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Home Page: www.sernova.com
The Stiller Centre
London,
ON
N6G 4X8
Canada
Phone:
519 858 5184
Officers
| Name | Title |
|---|---|
| Mr. Frank A. Holler MBA | Exec. Chairman |
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer |
| Mr. Douglas Maret | Chief Science Officer |
| Mr. Christopher Barnes | VP of Investor Relations |
Exchange: XETRA
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7641 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |